Medical and Science
BMS appoints new Country Medical Director in internal promotion
Medical: Bristol Myers Squibb (BMS) has announced the appointment of Dr Meredith Edwards as the new Country Medical Director of Australia and New Zealand, a promotion from her role as Associate Medical Director of Innovative Medicines.
Expressing her enthusiasm, Dr Edwards remarked “I am thrilled to step into this leadership position. The BMS mission to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases is one that deeply resonates with me. I am excited to continue collaborating with the talented team at BMS Australia in this new role.”
Dr Edwards emphasised the collective commitment shared by the team, stating “Together, our shared purpose is to bring our therapies to Australian patients, upholding BMS’s commitment to patients and scientific excellence. We are fortunate in Australia to have world-leading physicians and researchers and a number of centres of excellence for clinical trials to advance our understanding of disease management with investigational therapies.”
With a rich background encompassing two decades of experience in healthcare, spanning clinical medicine, research, life sciences consultancy, market access consultancy, and pharmaceutical industry roles in various international settings including the US and France, Dr Edwards brings a wealth of expertise to her new position.
She joined BMS in 2020 as the Associate Medical Director for Cardiovascular and Immunology, where she played a crucial role in advancing the company’s medical initiatives and launching significant treatments in these therapeutic areas.
Dr Edwards is a medical doctor who received her degree with honours (MBBS Hons) from the University of Tasmania. She then furthered her education with a Master of Public Health and Master of Business Administration from the University of Sydney, where she was awarded the Alek Safarian Scholarship.
In her new role, Dr Edwards will also join the InterContinental Medical and Australian Leadership Teams, where she looks forward to leveraging her extensive experience and insights to drive forward BMS’s mission in Australia and New Zealand.
Furthermore, with the recent promotion of Dr Edwards’ predecessor, Melinda Munns, to a global role based in Australia, BMS underscores its commitment to fostering career growth and offering international opportunities for the local team.
In reimagining healthcare, Health Industry HubTM is the ONLY one-stop-hub uniting the diversity of Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change. The exclusive leadership and influencer podcasts and vodcasts offer unparalleled insights and add immense value to our breaking news coverage.
The Health Industry HubTM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.
News & Trends - Pharmaceuticals
March PBAC agenda unveiled amid tensions over ‘unprecedented’ volume of submissions
The Department of Health has released the agenda for the March 2025 Pharmaceutical Benefits Advisory Committee (PBAC) meeting, unveiling plans […]
MoreNews & Trends - MedTech & Diagnostics
J&J MedTech exits DePuy Synthes spine portfolio
Johnson & Johnson MedTech will officially exit the DePuy Synthes Spine portfolio in Australia tomorrow, November 30, as part of […]
MoreNews & Trends - Pharmaceuticals
Home-grown hypertension polypill heads to regulatory approval
Australian-supported research has revealed remarkable Phase III clinical trial results for an innovative triple drug combination in the treatment of […]
MoreNews & Trends - Pharmaceuticals
Will Australia become first country to eliminate HIV transmission by 2030?
In the lead-up to World AIDS Day on December 1, the Albanese Government has unveiled the 9th National HIV Strategy, […]
More